Form 4: Tenaya Therapeutics CEO Receives Stock Grant
Insider Transaction (Form 4)
Faraz Ali, Chief Executive Officer and a Director of Tenaya Therapeutics, Inc., reported multiple transactions in common stock on September 10, 2026.
Summary
- Grant/award: acquired 122,000 Common Stock on September 10, 2026; holds 539,782 after (Direct).
- Grant/award: acquired 732,500 Stock Option (Right to buy) on September 10, 2026; holds 732,500 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Faraz Ali — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-10 | Grant/award | Common Stock | 122,000 | — | — | 539,782 |
| 2026-09-10 | Grant/award | Stock Option (Right to buy) | 732,500 | — | — | 732,500 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-10 | Grant/award (122,000 shares) |
| 2026-09-10 | Grant/award (732,500 shares) |
Keywords
insider transaction, Form 4, TNYA, Tenaya Therapeutics, Inc., neutral, Faraz Ali
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.